|
Identification and validation of prognostic models and survival predictions of T cell-inflamed related genes in patients with colorectal cancer
|
X. Shen   , Y. Zhang , Y. Dong , J. Qian |
| Department of Gastroenterology, Nantong First People's Hospital, Nantong, Jiangsu 226014, China , ntyybobo@163.com |
|
|
Abstract: (1061 Views) |
Background: The anti-tumor immune reaction has a critical part in the progression together with survival of colorectal cancer (CRC). The expression of T cell-inflamed gene as a potential indicator that predicts the reaction of immunogenic cancer types to checkpoint inhibitor immunotherapy, but its prognostic value in CRC is unclear. Materials and Methods: Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses identified enrichment analysis of T cell-inflamed associated genes. The prognostic model is built and the prognostic genes screened using the LASSO Cox regression model. Relationship among risk score, disease subtypes and immune infiltration was constructed. Besides, risk score was combined with clinicopathological features to further improve prognostic models and survival predictions. Results: We identified 14 T cell-inflamed associated genes were differential expressed in CRC tissues. GO along with KEGG analyses revealed that T cell-inflamed associated genes were implicated in the regulation of immune cells. Through LASSO Cox regression, a 5-gene prognostic model was constructed as well as classified all CRC patients into a low- or high-risk group or different disease subtypes (C1, C2 and C3). In the C3 group the OS rate of CRC patients was longer compared to the C1 group. Additionally, the prognosis Decision Curve Analysis (DCA) map displayed that the risk score was increased compared to the extreme curve and higher than other indicators, showing the strongest survival prediction ability. Conclusion: These results indicated that T cell-inflamed associated gene-based risk score reflected immune microenvironment features as well as predicted prognosis in CRC. |
|
| Keywords: Colorectal cancer, T cell, prognosis, immune. |
|
|
Full-Text [PDF 3348 kb]
(352 Downloads)
|
|
Type of Study: Original Research |
Subject:
Radiation Biology
|
|
|
|
|
|
|
| References |
1. 1. Li J, X Ma, D Chakravarti, S Shalapour and RA DePinho, Genetic and biological hallmarks of colorectal cancer. Genes Dev, 2021. 35(11-12): p. 787-820. [ DOI:10.1101/gad.348226.120] 2. Dekker E, PJ Tanis, JLA Vleugels, PM Kasi and MB Wallace, Colorectal cancer. Lancet, 2019. 394(10207): p. 1467-1480. [ DOI:10.1016/S0140-6736(19)32319-0] 3. Siegel RL, KD Miller, A Goding Sauer, SA Fedewa, LF Butterly, JC Anderson, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin, 2020. 70(3): p. 145-164. [ DOI:10.3322/caac.21601] 4. Zygulska AL and P Pierzchalski, Novel Diagnostic Biomarkers in Colorectal Cancer. Int J Mol Sci, 2022. 23(2). [ DOI:10.3390/ijms23020852] 5. Olenius T, L Koskenvuo, S Koskensalo, A Lepistö and C Böckelman, Long-term survival among colorectal cancer patients in Finland, 1991-2015: a nationwide population-based registry study. BMC Cancer, 2022. 22(1): p. 356. [ DOI:10.1186/s12885-022-09460-0] 6. Boukouris AE, M Theochari, D Stefanou, A Papalambros, E Felekouras, H Gogas, et al. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update. Crit Rev Oncol Hematol, 2022. 173: p. 103663. [ DOI:10.1016/j.critrevonc.2022.103663] 7. Bagchi S, R Yuan and EG Engleman, Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annu Rev Pathol, 2021. 16: p. 223-249. [ DOI:10.1146/annurev-pathol-042020-042741] 8. Carlino MS, J Larkin and GV Long, Immune checkpoint inhibitors in melanoma. Lancet, 2021. 398(10304): p. 1002-1014. [ DOI:10.1016/S0140-6736(21)01206-X] 9. Liu Z, JP Li, M Chen, M Wu, Y Shi, W Li, et al. Detecting Tumor Antigen-Specific T Cells via Interaction-Dependent Fucosyl-Biotinylation. Cell, 2020. 183(4): p. 1117-1133.e19. [ DOI:10.1016/j.cell.2020.09.048] 10. Garris CS and JJ Luke, Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response. Clin Cancer Res, 2020. 26(15): p. 3901-3907. [ DOI:10.1158/1078-0432.CCR-19-1321] 11. Hu J, A Yu, B Othmane, D Qiu, H Li, C Li, et al. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer. Theranostics, 2021. 11(7): p. 3089-3108. [ DOI:10.7150/thno.53649] 12. Li X, Y Xiang, F Li, C Yin, B Li and X Ke, WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment. Front Immunol, 2019. 10: p. 2293. [ DOI:10.3389/fimmu.2019.02293] 13. Baharom F, RA Ramirez-Valdez, A Khalilnezhad, S Khalilnezhad, M Dillon, D Hermans, et al. Systemic vaccination induces CD8(+) T cells and remodels the tumor microenvironment. Cell, 2022. 185(23): p. 4317-4332.e15. [ DOI:10.1016/j.cell.2022.10.006] 14. Ott PA, YJ Bang, SA Piha-Paul, ARA Razak, J Bennouna, JC Soria, et al. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. J Clin Oncol, 2019. 37(4): p. 318-327. [ DOI:10.1200/JCO.2018.78.2276] 15. Shah MA, T Kojima, D Hochhauser, P Enzinger, J Raimbourg, A Hollebecque, et al. T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer. Future Oncol, 2022. [ DOI:10.2217/fon-2021-1134] 16. Yin H, TA Harrison, SS Thomas, CL Sather, AL Koehne, RC Malen, et al. T cell-inflamed gene expression profile is associated with favorable disease-specific survival in non-hypermutated microsatellite-stable colorectal cancer patients. Cancer Med, 2022. [ DOI:10.1002/cam4.5429] 17. Niu D, Y Chen, H Mi, Z Mo and G Pang, The epiphany derived from T-cell-inflamed profiles: Pan-cancer characterization of CD8A as a biomarker spanning clinical relevance, cancer prognosis, immunosuppressive environment, and treatment responses. Front Genet, 2022. 13: p. 974416. [ DOI:10.3389/fgene.2022.974416] 18. Wang R, Y Ma, S Zhan, G Zhang, L Cao, X Zhang, et al. B7-H3 promotes colorectal cancer angiogenesis through activating the NF-κB pathway to induce VEGFA expression. Cell Death Dis, 2020. 11(1): p. 55. [ DOI:10.1038/s41419-020-2252-3] 19. Ingebrigtsen VA, K Boye, JM Nesland, A Nesbakken, K Flatmark and Ø Fodstad, B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome. BMC Cancer, 2014. 14: p. 602. [ DOI:10.1186/1471-2407-14-602] 20. Wu Z, X Huang, X Han, Z Li, Q Zhu, J Yan, et al. The chemokine CXCL9 expression is associated with better prognosis for colorectal carcinoma patients. Biomed Pharmacother, 2016. 78: p. 8-13. [ DOI:10.1016/j.biopha.2015.12.021] 21. Verbeke H, S Struyf, G Laureys and J Van Damme, The expression and role of CXC chemokines in colorectal cancer. Cytokine Growth Factor Rev, 2011. 22(5-6): p. 345-58. [ DOI:10.1016/j.cytogfr.2011.09.002] 22. Hu Y, J Ding, C Wu, H Gao, M Ge, Q Shao, et al. Differential Expression and Prognostic Correlation of Immune Related Factors Between Right and Left Side Colorectal Cancer. Front Oncol, 2022. 12: p. 845765. [ DOI:10.3389/fonc.2022.845765] |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Shen X, Zhang Y, Dong Y, Qian J. Identification and validation of prognostic models and survival predictions of T cell-inflamed related genes in patients with colorectal cancer. Int J Radiat Res 2024; 22 (3) :595-602 URL: http://ijrr.com/article-1-5593-en.html
|
